Literature DB >> 20659058

'To prove this is the industry's best hope': big tobacco's support of research on the genetics of nicotine addiction.

Kenneth R Gundle1, Molly J Dingel, Barbara A Koenig.   

Abstract

BACKGROUND: New molecular techniques focus a genetic lens upon nicotine addiction. Given the medical and economic costs associated with smoking, innovative approaches to smoking cessation and prevention must be pursued; but can sound research be manipulated by the tobacco industry?
METHODOLOGY: The chronological narrative of this paper was created using iterative reviews of primary sources (the Legacy Tobacco Documents), supplemented with secondary literature to provide a broader context. The empirical data inform an ethics and policy analysis of tobacco industry-funded research.
FINDINGS: The search for a genetic basis for smoking is consistent with industry's decades-long plan to deflect responsibility away from the tobacco companies and onto individuals' genetic constitutions. Internal documents reveal long-standing support for genetic research as a strategy to relieve the tobacco industry of its legal responsibility for tobacco-related disease.
CONCLUSIONS: Industry may turn the findings of genetics to its own ends, changing strategy from creating a 'safe' cigarette to defining a 'safe' smoker.

Entities:  

Mesh:

Year:  2010        PMID: 20659058      PMCID: PMC2911634          DOI: 10.1111/j.1360-0443.2010.02940.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  46 in total

Review 1.  Scope and impact of financial conflicts of interest in biomedical research: a systematic review.

Authors:  Justin E Bekelman; Yan Li; Cary P Gross
Journal:  JAMA       Date:  2003 Jan 22-29       Impact factor: 56.272

2.  Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials.

Authors:  Mohit Bhandari; Jason W Busse; Dianne Jackowski; Victor M Montori; Holger Schünemann; Sheila Sprague; Derek Mears; Emil H Schemitsch; Dianne Heels-Ansdell; P J Devereaux
Journal:  CMAJ       Date:  2004-02-17       Impact factor: 8.262

Review 3.  Assessing internal tobacco industry knowledge of the neurobiology of tobacco dependence.

Authors:  Geoffrey Ferris Wayne; Gregory N Connolly; Jack E Henningfield
Journal:  Nicotine Tob Res       Date:  2004-12       Impact factor: 4.244

4.  Differential citation rates of major cardiovascular clinical trials according to source of funding: a survey from 2000 to 2005.

Authors:  David Conen; Jose Torres; Paul M Ridker
Journal:  Circulation       Date:  2008-09-08       Impact factor: 29.690

Review 5.  Genetics and behavioral medicine.

Authors:  G E McClearn; G P Vogler; R Plomin
Journal:  Behav Med       Date:  1996       Impact factor: 3.104

Review 6.  Behavioral genetics.

Authors:  G E McClearn
Journal:  Annu Rev Genet       Date:  1970       Impact factor: 16.830

Review 7.  Tobacco industry use of judicial seminars to influence rulings in products liability litigation.

Authors:  L C Friedman
Journal:  Tob Control       Date:  2006-04       Impact factor: 7.552

8.  The perils of ignoring history: Big Tobacco played dirty and millions died. How similar is Big Food?

Authors:  Kelly D Brownell; Kenneth E Warner
Journal:  Milbank Q       Date:  2009-03       Impact factor: 4.911

Review 9.  Tobacco industry efforts undermining evidence linking secondhand smoke with cardiovascular disease.

Authors:  Elisa K Tong; Stanton A Glantz
Journal:  Circulation       Date:  2007-10-16       Impact factor: 29.690

Review 10.  Relation of study quality, concordance, take home message, funding, and impact in studies of influenza vaccines: systematic review.

Authors:  T Jefferson; C Di Pietrantonj; M G Debalini; A Rivetti; V Demicheli
Journal:  BMJ       Date:  2009-02-12
View more
  9 in total

1.  Integrating genetic studies of nicotine addiction into public health practice: stakeholder views on challenges, barriers and opportunities.

Authors:  M J Dingel; A D Hicks; M E Robinson; B A Koenig
Journal:  Public Health Genomics       Date:  2011-07-09       Impact factor: 2.000

Review 2.  The Influence of Industry Sponsorship on the Research Agenda: A Scoping Review.

Authors:  Alice Fabbri; Alexandra Lai; Quinn Grundy; Lisa Anne Bero
Journal:  Am J Public Health       Date:  2018-09-25       Impact factor: 9.308

3.  Addiction industry studies: understanding how proconsumption influences block effective interventions.

Authors:  Peter J Adams
Journal:  Am J Public Health       Date:  2013-02-14       Impact factor: 9.308

4.  The tobacco industry, researchers, and ethical access to UK Biobank: using the public interest and public good.

Authors:  Benjamin James Capps; Yvette van der Eijk
Journal:  Am J Public Health       Date:  2014-08-14       Impact factor: 9.308

5.  Unwarranted optimism in media portrayals of genetic research on addiction overshadows critical ethical and social concerns.

Authors:  Jenny E Ostergren; Molly J Dingel; Jennifer B McCormick; Barbara A Koenig
Journal:  J Health Commun       Date:  2015-03-25

Review 6.  Being more realistic about the public health impact of genomic medicine.

Authors:  Wayne D Hall; Rebecca Mathews; Katherine I Morley
Journal:  PLoS Med       Date:  2010-10-12       Impact factor: 11.069

7.  Framing Nicotine Addiction as a "Disease of the Brain": Social and Ethical Consequences.

Authors:  Molly J Dingel; Katrina Karkazis; Barbara A Koenig
Journal:  Soc Sci Q       Date:  2011-10-18

8.  Tobacco and the invention of quitting: a history of gender, excess and will-power.

Authors:  Cameron White; John L Oliffe; Joan L Bottorff
Journal:  Sociol Health Illn       Date:  2013-04-21

9.  Challenges in translational research: the views of addiction scientists.

Authors:  Jenny E Ostergren; Rachel R Hammer; Molly J Dingel; Barbara A Koenig; Jennifer B McCormick
Journal:  PLoS One       Date:  2014-04-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.